Drug combo for advanced colorectal cancer that hasn't spread to the liver
Part of Cancer, Digestive system clinical trials.
This trial tests a combination of two drugs (anlotinib and sintilimab) as a first treatment for people with advanced colorectal cancer that has spread to places other than the liver, who do not want chemotherapy. The goal is to see if this targeted therapy can help control the cancer.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have advanced colorectal cancer that has spread to areas other than the liver.
- You have not had chemotherapy for advanced disease (or if you did, it was at least a year ago).
- You are willing to not receive chemotherapy for this cancer.
- You have at least one tumor that can be measured on scans.
- You are 18 or older and in generally good health (able to care for yourself).
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a new combination of two drugs, pirfenidone and sintilimab, added to standard chemotherapy before surgery for colorectal cancer that has spread to the lining of the abdomen (peritoneal metastasis). The goal is to see if this combination helps shrink the cancer more effectively.
This trial tests a new combination of three drugs for people with advanced colorectal cancer that has not responded to previous treatments. The goal is to see if this combination can help shrink tumors or slow the cancer's growth.
This trial tests combinations of immunotherapy drugs for people with colorectal cancer that has spread to the liver and is scheduled for surgery. The goal is to see if these treatments are safe and effective before and after the operation.
This trial tests a combination of three drugs—tucidinostat, sintilimab, and bevacizumab—for people with a specific type of advanced colorectal cancer (MSS or pMMR) that has gotten worse after standard treatments. The goal is to see if this new mix can help shrink or slow the tumor.
This trial tests a combination of four drugs for people with a specific type of advanced colorectal cancer that has a BRAF V600E mutation and is microsatellite stable. The goal is to see if this combination can shrink tumors or slow the cancer's growth.
This study tests a new combination of short-course radiation followed by two targeted drugs (fruquintinib and sintilimab) compared to standard therapy (bevacizumab and capecitabine) for people with advanced colorectal cancer who cannot tolerate strong chemotherapy. It aims to see if this gentler approach works as well or better.
Hear when a new Colorectal cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.